Sabrina de Souza is an Associate Director Real-World Data Scientist in the Patient-Focused Real-World Evidence unit at Merck Healthcare. She initiated her education in Applied Mathematics in Paris and holds a Master degree in Biostatistics (Montpellier II), 2005, and an advanced Master degree in Public Health (Pasteur Institute / CNAM), 2015.
She started to work as a consultant (from 2006) for big pharmaceutical companies before joining Boehringer Ingelheim Global Epidemiology and Real-World Data Analytics Centre of Excellence in 2018 and then Merck Epidemiology unit in 2021.
She focuses her expertise on Non-Interventional Studies and on the generation of Real-World Evidence using data-sources from various regions (Europe, US, Asia). She takes part in cross-functional working groups to enhance efficiency in Real-World Data governance practices and actively participates in innovative projects using Real-World Data. She is co-author of several peer-reviewed articles published in medical and epidemiological journals.
Laurent Laffineur is Head of Business Development for Cascador Health, a Belgian company that provides RWD solutions for companies in the life sciences industry. Founded in 2021, Cascador Health developed the Cascador Ignite platform, ensuring that medical data can be shared and used for research projects in a GDPR compliant way.
Having spent 20+ years with pharma and medical devices companies, Laurent is now responsible for the execution of international projects and ensuring that Cascador collaborates with datapartners across Europe to answer the needs of the clients.
Laurent holds a Master’s Degree in Pharmacy at the University Antwerp and is an alumni of INSEAD and the London Business School.
Maike Sauer leads the Network & Commercial Partnerships team and is responsible for expanding Flatiron's strategic partnerships in Germany. She has been with Flatiron since 2021, bringing her experience from the pharmaceutical industry at AstraZeneca, strategic consulting at Oliver Wyman, and her PhD in tumor research, significantly contributing to the establishment and positioning of Flatiron in Germany. Maike studied biomedical sciences in Marburg before conducting oncology research at NUS in Singapore and the University Hospital Cologne, where she earned her PhD in tumor immunology.
Dr. Michael Happich is Senior Director - Value Evidence Outcomes Intl - at Eli Lilly based in Bad Homburg, Germany. He leads an international team of HTA & RWE scientists to support drug launches, HTA submissions and observational research for autoimmune diseases outside the US. Before joining the industry 18 years ago, he worked at the Helmholtz-Research Center in Munich. He is lecturer on pharmacoeconomics at the Goethe University Frankfurt, and Neubrandenburg University of applied sciences.
Vandana’s role involves development of NICE’s Real World Evidence framework and helping to transform NICE’s use of real-world data across guidance products. Vandana is also involved with upskilling individuals within and externally to the organisation, contributing to training workshops and technical forums. Before joining NICE, Vandana led the management of the national rare disease registry for Duchenne muscular dystrophy at University College London. Prior to this, she has worked in clinical and research capacity within academia on several multi-sector collaborative projects within the NHS. Vandana has an MSc in research methods and a PhD in public health.
Ralf has more than 30 years of experience in Data analysis, marketing and consulting for the pharmaceutical industry. In the course of his career, he has worked as an international consultant for many pharmaceutical companies with a focus on big data, statistics, analyses and return on investment. Ralf started his career at the US pharmaceutical manufacturing company Upjohn. He has been with Cegedim Health Data since 2020, having previously worked i.a. for IMS Health, Kantar Health, Cegedim Strategic Data and as High-Performance Coach. Graduating from the International Management School (Intermas), he holds an MBA and is a book author.
Martin graduated with a BSc Statistics and MSc Medical Statistics degree. Having worked as a trial and project statistician in the UK, Germany, Switzerland and Italy at pharmaceutical manufacturers and CROs, Martin has been responsible for the statistical analysis and design of clinical trials across all phases of development. His current role is that of Scientific Director for Numerus, a statistical consultancy specialising in late phase development, HTA and RWE. With 28 years of industry experience, Martin now advises Clinical Development and Market Access Teams on the requirements for HTA in Germany as well as the for the European Joint Clinical Assessment (JCA), with an emphasis on oncology.
Dr Lewis Carpenter is Director of Real-World Evidence at Arcturis and has over 14-years’ experience in the design and conduct of real-world evidence studies. He holds a PhD in Medical Statistics and conducted a post-doc at King’s College London specialising in longitudinal analysis methods using real-world data generated from electronic health records and disease registries. Over the last 4-years at Arcturis, he has developed and oversees the RWE team of epidemiologists and medical statisticians to leverage Arcturis’ unique access to UK NHS data to generate vital RWE insights for pharmaceutical and biotech companies. This evidence is used to support the development, and regulatory/reimbursement process for new effective therapies across multiple therapeutic areas, including the development and analysis of external control arms for HTA submissions.
Sandeep Kiri has over thirteen years of experience in market access with a strong focus on health economics and health technology assessment. He has been in the global function at UCB for five years and is currently the Global Head of Health Economics and HTA Evidence with a keen focus on developing the right evidence for payers in order to demonstrate the full value of interventions.
Gustavo OLIVERA is an HEOR Senior Expert: PhD holder + 14 years of experience. His background comprises (but is not limited to) 9 years of Global HEOR and Market Access operations in a top 10 pharma company, with the daily mission of demonstrating the value of novel interventions to leaders of different types of healthcare systems around the world, to improve public health and quality of life. Strong background and experience on: Market Access strategy and execution; Health Economics studies; Evidence Generation; Value Assessment; Value Demonstration. During these years, he has led multiple external partnerships and outsourced Projects; HTA and reimbursement file submissions; direct interactions with external stakeholders (health authorities, decision-makers, technical advisory groups, supranational public health organizations, etc). Main interests: Public Health, The evolution of pharma industry; HTA trends around the world, Novel HEOR methods and approaches; Real World Evidence; Computational Modeling & Data Analysis.
Donia Bahloul is the Global Health Economics and Value Assessment Lead at Sanofi, supporting Dermatology Franchise.She is responsible for the development and implementation of scientifically robust integrated evidence strategies that drive successful launch and access of portfolio drug assets. She is also involved in executing high-impact HTA deliverables and real-world studies to support affiliates’ local submissions.
Donia is Pharmacist by training and holds a master’s degree in health economics from the University of Paris-Est Créteil, France as well as a European Market Access University Diploma.
JT leads AI programs at Apheris, specializing in AI for healthcare and life sciences industries. He holds a PhD in economics with a focus on digital health and privacy. JT has led forward-deployed teams across several industries, including global health and healthcare, and worked for institutions such as the US CDC or Palantir Technologies. He focuses on integrating responsible AI governance programs that meet evolving regulatory and organizational requirements.
Alexandre Templier has been working in the field of Life Sciences for more than 28 years. Passionate about Artificial Intelligence and data-driven decision-making in complex environments, Alexandre has dedicated his professional career to improving healthcare products and medical practice through Real World Data analytics and AI. Co-founder of Quinten Health and President of Quinten Health, he is particularly involved in the development of Quinten Health's activities within the healthcare sector (including projects for industry, healthcare providers, research institutions, and healthcare regulatory agencies). Alexandre was associate professor at Ecole Nationale Supérieure d'Arts & Métiers Paris Tech from 2001 to 2013.
Prof. Dr. Thomas Wilke works as Senior Scientist at GIPAM, a Global Health Care Consultancy with offices in the US, UK and GER (www.gipam-health.com). In addition, he works as Professor at University of Wismar and is leading a University-affiliated research institute focusing on RWE (www.ipam-wismar.de). He has >20 years experience in RWE studies, with a specific focus on database studies and innovative software architectures to support such studies.
Remon Helmy is a Senior Manager, Health Economics and Outcomes Research at Alexion, AstraZeneca Rare Disease Business Unit. He is a registered pharmacist with a master’s degree in Health Economics from the University of Heidelberg, Germany and a PhD with a focus on Treatment Adherence from the University of Basel, Switzerland. He also holds a Master of Business Administration. He has over 14 years of experience across different settings of pharmacy practice, academia, consulting, and the pharmaceutical industry.
Thomas Gilboy is the Product Owner at Access Infinity for our Market Access Digital Tools. As Product Owner, he leads the product development and “blue sky thinking” of what is possible within the digital space for Market Access. Before Access Infinity, Tom worked for 10 years within Market Access in consulting and at ViiV.
In consulting Tom delivered over 100 projects covering a broad range of Market Access topics from early pipeline decisions through to end-of-life cycle planning, across a broad range of therapy areas. At ViiV, Tom covered the successful European Market Access for one of their launching HIV brands.
Jeffrey Brown, PhD, Chief Scientific Officer at TriNetX and Lecturer (part-time) at Harvard Medical School (HMS), is an internationally recognized expert in the use of real-world data to support the evidentiary needs of regulatory agencies and medical product sponsors. He has 25+ years of research experience using real-world data, particularly in federated research networks, most recently as an Associate Professor in the Department of Population Medicine (HMS) and a trusted consultant to numerous research groups and pharmaceutical companies. At HMS he served as the Lead Data Scientist for the FDA Sentinel Operations Center and as PI for several multi-site pharmacoepidemiologic studies to support FDA and EMA regulatory requirements.
